| Year |
Citation |
Score |
| 2023 |
Sun CX, Daniel P, Bradshaw G, Shi H, Loi M, Chew N, Parackal S, Tsui V, Liang Y, Koptyra M, Adjumain S, Sun C, Chong WC, Fernando D, Drinkwater C, ... ... Firestein R, et al. Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. Cancer Cell. PMID 37001527 DOI: 10.1016/j.ccell.2023.03.007 |
0.343 |
|
| 2022 |
Dicara DM, Bhakta S, Go MA, Ziai J, Firestein R, Forrest B, Gu C, Leong SR, Lee G, Yu SF, Polson AG, Agard NJ. Development of T-cell engagers selective for cells co-expressing two antigens. Mabs. 14: 2115213. PMID 36206404 DOI: 10.1080/19420862.2022.2115213 |
0.308 |
|
| 2021 |
Sooraj D, Sun C, Doan A, Garama DJ, Dannappel MV, Zhu D, Chua HK, Mahara S, Wan Hassan WA, Tay YK, Guanizo A, Croagh D, Prodanovic Z, Gough DJ, Wan C, ... Firestein R, et al. MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase. Molecular Cell. PMID 34910943 DOI: 10.1016/j.molcel.2021.11.015 |
0.346 |
|
| 2018 |
Daemen A, Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Peterson D, Liederer BM, de la Cruz C, Sangaraju D, Jaochico A, Zhao X, Sandoval W, Hunsaker T, ... Firestein R, et al. Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. Cell Metabolism. PMID 30043751 DOI: 10.1016/J.Cmet.2018.06.003 |
0.442 |
|
| 2018 |
Raab M, Sanhaji M, Matthess Y, Hörlin A, Lorenz I, Dötsch C, Habbe N, Waidmann O, Kurunci-Csacsko E, Firestein R, Becker S, Strebhardt K. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nature Communications. 9: 1106. PMID 29549256 DOI: 10.1038/S41467-018-03494-4 |
0.447 |
|
| 2017 |
Bhakta S, Crocker LM, Chen Y, Hazen M, Schutten MM, Li D, Kuijl C, Ohri R, Zhong F, Poon KA, Go MAT, Cheng E, Piskol R, Firestein R, Fourie-O'Donohue A, et al. An anti-GDNF Family Receptor Alpha 1(GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer. Molecular Cancer Therapeutics. PMID 29282299 DOI: 10.1158/1535-7163.Mct-17-0813 |
0.458 |
|
| 2017 |
Mahara S, Firestein R. Targeting the seeds of small cell lung cancer. Annals of Translational Medicine. 5: 113. PMID 28361078 DOI: 10.21037/Atm.2017.01.74 |
0.501 |
|
| 2016 |
Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 27: 2124-2130. PMID 27793850 DOI: 10.1093/Annonc/Mdw401 |
0.43 |
|
| 2016 |
Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, Vanderbilt A, Tinianow J, Gupta N, Li D, Firestein R, Marik J, Scales SJ, Williams SP. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET. Molecular Cancer Therapeutics. PMID 27760836 DOI: 10.1158/1535-7163.Mct-16-0449 |
0.454 |
|
| 2016 |
Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, ... ... Firestein R, et al. Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nature Chemical Biology. PMID 27479743 DOI: 10.1038/Nchembio.2143 |
0.371 |
|
| 2016 |
Williams SP, Ogasawara A, Tinianow JN, Flores JE, Kan D, Lau J, Go MA, Vanderbilt AN, Gill HS, Miao L, Goldsmith J, Rubinfeld B, Mao W, Firestein R, Yu SF, et al. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1. Oncotarget. PMID 27029064 DOI: 10.18632/Oncotarget.8390 |
0.434 |
|
| 2016 |
Koehler MF, Bergeron P, Blackwood EM, Bowman K, Clark KR, Firestein R, Kiefer JR, Maskos K, McCleland ML, Orren L, Salphati L, Schmidt S, Schneider EV, Wu J, Beresini MH. Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells. Acs Medicinal Chemistry Letters. 7: 223-8. PMID 26985305 DOI: 10.1021/Acsmedchemlett.5B00278 |
0.329 |
|
| 2016 |
McCleland ML, Mesh K, Lorenzana E, Chopra VS, Segal E, Watanabe C, Haley B, Mayba O, Yaylaoglu M, Gnad F, Firestein R. CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. The Journal of Clinical Investigation. PMID 26752646 DOI: 10.1172/Jci83265 |
0.472 |
|
| 2016 |
Firestein R, McCleland M, Mesh K, Gnad F. Abstract 406: Enhancer templated RNAs as predictors of therapeutic response to epigenetic therapy Cancer Research. 76: 406-406. DOI: 10.1158/1538-7445.Am2016-406 |
0.455 |
|
| 2015 |
Storm EE, Durinck S, de Sousa E Melo F, Tremayne J, Kljavin N, Tan C, Ye X, Chiu C, Pham T, Hongo JA, Bainbridge T, Firestein R, Blackwood E, Metcalfe C, Stawiski EW, et al. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function. Nature. PMID 26700806 DOI: 10.1038/Nature16466 |
0.404 |
|
| 2015 |
Junttila MR, Mao W, Wang X, Wang BE, Pham T, Flygare J, Yu SF, Yee S, Goldenberg D, Fields C, Eastham-Anderson J, Singh M, Vij R, Hongo JA, Firestein R, et al. Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Science Translational Medicine. 7: 314ra186. PMID 26582901 DOI: 10.1126/Scitranslmed.Aac7433 |
0.492 |
|
| 2015 |
McCleland ML, Soukup TM, Liu SD, Esensten JH, de Sousa E Melo F, Yaylaoglu M, Warming S, Roose-Girma M, Firestein R. Cdk8 deletion in the Apc(Min) murine tumor model represses EZH2 activity and accelerates tumorigenesis. The Journal of Pathology. PMID 26235356 DOI: 10.1002/Path.4596 |
0.404 |
|
| 2015 |
Lin K, Rubinfeld B, Zhang C, Firestein R, Harstad E, Roth L, Tsai SP, Schutten M, Xu K, Hristopoulos M, Polakis P. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26156394 DOI: 10.1158/1078-0432.Ccr-14-3383 |
0.452 |
|
| 2015 |
Asundi J, Crocker L, Tremayne J, Chang P, Sakanaka C, Tanguay J, Spencer S, Chalasani S, Luis E, Gascoigne K, Desai R, Raja R, Friedman BA, Haverty PM, Polakis P, ... Firestein R, et al. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3252-62. PMID 25862760 DOI: 10.1158/1078-0432.Ccr-15-0156 |
0.388 |
|
| 2015 |
Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D, Ohri R, Raab H, Hass PE, Pham T, Firestein R, Li D, Schutten M, Stagg NJ, Ogasawara A, et al. An anti-b7-h4 antibody-drug conjugate for the treatment of breast cancer. Molecular Pharmaceutics. 12: 1717-29. PMID 25853436 DOI: 10.1021/Mp5007745 |
0.407 |
|
| 2015 |
Ryner L, Guan Y, Firestein R, Xiao Y, Choi Y, Rabe C, Lu S, Fuentes E, Huw LY, Lackner MR, Fu L, Amler LC, Bais C, Wang Y. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2941-51. PMID 25838397 DOI: 10.1200/Jco.2015.33.15_Suppl.E16581 |
0.401 |
|
| 2015 |
Yu N, Kakunda M, Pham V, Lill JR, Du P, Wongchenko M, Yan Y, Firestein R, Huang X. HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin. Molecular and Cellular Biology. 35: 1390-400. PMID 25645927 DOI: 10.1128/Mcb.01307-14 |
0.315 |
|
| 2015 |
Wang Y, Firestein R, Ryner L, Darbonne W, Guan Y, Lu S, Choi Y, Xiao Y, Polakis P, Suttmann B, Desai R, Fu L, Saad O, Poon KA, Denker M, et al. Abstract POSTER-THER-1441: Biomarker evaluation of phase 1 clinical trials of antibody-drug conjugates (ADCs) in platinum resistant ovarian cancer Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1441 |
0.454 |
|
| 2015 |
Asundi J, Crocker L, Tremayne J, Polakis P, Firestein R. Abstract 947: An antibody drug conjugate (ADC) directed to lymphocyte antigen 6 complex, locus E (LY6E) delivers targeted chemotherapy to a wide range of solid tumor malignancies Cancer Research. 75: 947-947. DOI: 10.1158/1538-7445.Am2015-947 |
0.499 |
|
| 2015 |
Danila DC, Scher HI, Szafer-Glusman E, Herkal A, Suttmann R, Fleisher M, Schreiber NA, Curtis K, Gilbert H, Maslyar D, Fine B, Firestein R, Mamounas M, Lackner MR, Kabbarah O. Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Cancer Research. 75: 4310-4310. DOI: 10.1158/1538-7445.Am2015-4310 |
0.419 |
|
| 2014 |
Shames D, Kowanetz M, Xiao Y, Choi Y, D'Arcangelo M, Behrens C, Solis LM, Koeppen H, Firestein R, Wang Y, Mocci S, Boyle TA, Lund-Iversen M, Bowden C, Amler LC, et al. 196PPREVALENCE, PROGNOSTIC SIGNIFICANCE, AND OVERLAP OF ACTIONABLE BIOMARKERS IN NSCLC. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv67. PMID 28172225 DOI: 10.1093/Annonc/Mdu326.30 |
0.392 |
|
| 2014 |
D'Arcangelo M, Brustugun OT, Xiao Y, Choi Y, Behrens C, Solis LM, Wang Y, Firestein R, Boyle TA, Lund-Iversen M, Rivard CJ, Helland Å, Wistuba I, Hirsch FR, Shames D. 194PPREVALENCE AND PROGNOSTIC SIGNIFICANCE OF SODIUM-DEPENDENT PHOSPHATE TRANSPORTER 2B (NAPI2B) PROTEIN EXPRESSION IN NON-SMALL CELL LUNG CANCER (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv66-iv67. PMID 28170646 DOI: 10.1093/Annonc/Mdu326.28 |
0.399 |
|
| 2014 |
Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, Rangell L, Barry-Hamilton V, Luis E, Chuh J, Zhang Y, Ingle GS, Fourie-O'Donohue A, Kozak KR, Ross S, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Molecular Cancer Therapeutics. 13: 2630-40. PMID 25249555 DOI: 10.1158/1535-7163.Mct-14-0487-T |
0.492 |
|
| 2014 |
Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn C, Jhunjhunwala S, Lawrence M, Liu H, Wan Y, Chopra V, Yaylaoglu MB, ... ... Firestein R, et al. Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. Nature Communications. 5: 3830. PMID 24807215 DOI: 10.1038/Ncomms4830 |
0.412 |
|
| 2014 |
Adler AS, McCleland ML, Yee S, Yaylaoglu M, Hussain S, Cosino E, Quinones G, Modrusan Z, Seshagiri S, Torres E, Chopra VS, Haley B, Zhang Z, Blackwood EM, Singh M, ... ... Firestein R, et al. An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth. Genes & Development. 28: 1068-84. PMID 24788092 DOI: 10.1101/Gad.237206.113 |
0.466 |
|
| 2014 |
Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Chuh J, Zhang Y, Berry L, Bostrom J, Luis E, O'Donohue AF, Kozak KR, Ross S, Dennis MS, Tibbitts J, et al. Abstract 4494: A clinical candidate anti-mesothelin-MMAE antibody-drug conjugate (ADC) for therapy of mesothelin-expressing cancers Cancer Research. 74: 4494-4494. DOI: 10.1158/1538-7445.Am2014-4494 |
0.478 |
|
| 2013 |
Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, ... ... Firestein R, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 23: 603-17. PMID 23680147 DOI: 10.1016/J.Ccr.2013.04.012 |
0.419 |
|
| 2013 |
Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, Diaz D, Merchant M, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Research. 73: 3132-44. PMID 23539443 DOI: 10.1158/0008-5472.Can-12-4562 |
0.382 |
|
| 2013 |
McCleland ML, Adler AS, Deming L, Cosino E, Lee L, Blackwood EM, Solon M, Tao J, Li L, Shames D, Jackson E, Forrest WF, Firestein R. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 773-84. PMID 23224736 DOI: 10.1158/1078-0432.Ccr-12-2638 |
0.344 |
|
| 2013 |
Boswell CA, Mundo EE, Firestein R, Zhang C, Mao W, Gill H, Young C, Ljumanovic N, Stainton S, Ulufatu S, Fourie A, Kozak KR, Fuji R, Polakis P, Khawli LA, et al. An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2. British Journal of Pharmacology. 168: 445-57. PMID 22889168 DOI: 10.1111/J.1476-5381.2012.02138.X |
0.387 |
|
| 2013 |
Liu B, Song K, Kwong M, Gao M, Hong R, Nannini M, Sampath D, Belvin M, Peterson D, Evangelista M, Daemen A, Firestein R, Hatzivassiliou G. Abstract 4618: Elucidating the role of distinct glutaminase isoforms in cancer. Cancer Research. 73: 4618-4618. DOI: 10.1158/1538-7445.Am2013-4618 |
0.487 |
|
| 2013 |
Ryner L, Fourie A, Tsai SP, Scales S, Kozak K, Firestein R, Guan Y, Do A, Wang Y. Abstract 3213: A rapid, sensitive and quantitative method to measure protein biomarkers MUC16 and MSLN from archived clinical samples using TaqMan proximity ligation assays. Cancer Research. 73: 3213-3213. DOI: 10.1158/1538-7445.Am2013-3213 |
0.397 |
|
| 2013 |
Adler A, Jiang Z, McCleland M, Blackwood E, Yee S, Haley B, Stephan J, Hussain S, Chopra V, Firestein R. Abstract 3203: The tri-snRNP spliceosome complex is required for MYC-dependent cancer growth. Cancer Research. 73: 3203-3203. DOI: 10.1158/1538-7445.Am2013-3203 |
0.452 |
|
| 2012 |
McCleland ML, Adler AS, Shang Y, Hunsaker T, Truong T, Peterson D, Torres E, Li L, Haley B, Stephan JP, Belvin M, Hatzivassiliou G, Blackwood EM, Corson L, Evangelista M, ... ... Firestein R, et al. An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. Cancer Research. 72: 5812-23. PMID 23139210 DOI: 10.1158/0008-5472.Can-12-1098 |
0.442 |
|
| 2012 |
Chen Y, Chalouni C, Tan C, Clark R, Venook R, Ohri R, Raab H, Firestein R, Mallet W, Polakis P. The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma. The Journal of Biological Chemistry. 287: 24082-91. PMID 22613716 DOI: 10.1074/Jbc.M112.361485 |
0.398 |
|
| 2012 |
Adler AS, McCleland ML, Truong T, Lau S, Modrusan Z, Soukup TM, Roose-Girma M, Blackwood EM, Firestein R. CDK8 maintains tumor dedifferentiation and embryonic stem cell pluripotency. Cancer Research. 72: 2129-39. PMID 22345154 DOI: 10.1158/0008-5472.Can-11-3886 |
0.463 |
|
| 2011 |
Asundi J, Reed C, Arca J, McCutcheon K, Ferrando R, Clark S, Luis E, Tien J, Firestein R, Polakis P. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 965-75. PMID 21245091 DOI: 10.1158/1078-0432.Ccr-10-2340 |
0.432 |
|
| 2011 |
McCleland M, Adler A, Firestein R. Abstract 5191: Dual roles for CDK8 in cancer and stem cell maintenance Cancer Research. 71: 5191-5191. DOI: 10.1158/1538-7445.Am2011-5191 |
0.534 |
|
| 2010 |
Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, Schinzel AC, Wittner B, Silver SJ, Root DE, Boehm JS, Ramaswamy S, Lander ES, Hahn WC. CK1epsilon is required for breast cancers dependent on beta-catenin activity. Plos One. 5: e8979. PMID 20126544 DOI: 10.1371/Journal.Pone.0008979 |
0.398 |
|
| 2010 |
Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S. CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival. International Journal of Cancer. Journal International Du Cancer. 126: 2863-73. PMID 19790197 DOI: 10.1002/Ijc.24908 |
0.438 |
|
| 2010 |
Mao W, Tien J, Goldenberg D, Stawicki S, Vij R, Xia X, Hongo J, Ross S, Kozak K, Firestein R, Wu Y, Spencer S, Polakis P. Abstract 4289: Early study on LGR5/GPR49 molecule as a potential colon cancer stem cell target for the antibody conjugated drug treatment Cancer Research. 70: 4289-4289. DOI: 10.1158/1538-7445.Am10-4289 |
0.516 |
|
| 2009 |
Firestein R, Hahn WC. Revving the Throttle on an oncogene: CDK8 takes the driver seat. Cancer Research. 69: 7899-901. PMID 19808961 DOI: 10.1158/0008-5472.Can-09-1704 |
0.363 |
|
| 2009 |
Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 22: 922-32. PMID 19430421 DOI: 10.1038/Modpathol.2009.49 |
0.437 |
|
| 2009 |
Hahn WC, Dunn IF, Kim SY, Schinzel AC, Firestein R, Guney I, Boehm JS. Integrative genomic approaches to understanding cancer. Biochimica Et Biophysica Acta. 1790: 478-84. PMID 19364473 DOI: 10.1016/J.Bbagen.2009.02.003 |
0.454 |
|
| 2008 |
Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 455: 547-51. PMID 18794900 DOI: 10.1038/Nature07179 |
0.431 |
|
| 2008 |
Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. Plos One. 3: e2020. PMID 18414679 DOI: 10.1371/Journal.Pone.0002020 |
0.443 |
|
| 2007 |
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 129: 1065-79. PMID 17574021 DOI: 10.1016/J.Cell.2007.03.052 |
0.42 |
|
| 2002 |
Firestein R, Nagy PL, Daly M, Huie P, Conti M, Cleary ML. Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Sbf1. The Journal of Clinical Investigation. 109: 1165-72. PMID 11994405 DOI: 10.1172/Jci12589 |
0.323 |
|
| 2000 |
Firestein R, Cui X, Huie P, Cleary ML. Set domain-dependent regulation of transcriptional silencing and growth control by SUV39H1, a mammalian ortholog of Drosophila Su(var)3-9. Molecular and Cellular Biology. 20: 4900-9. PMID 10848615 DOI: 10.1128/Mcb.20.13.4900-4909.2000 |
0.33 |
|
| 1998 |
Cui X, De Vivo I, Slany R, Miyamoto A, Firestein R, Cleary ML. Association of SET domain and myotubularin-related proteins modulates growth control. Nature Genetics. 18: 331-7. PMID 9537414 DOI: 10.1038/Ng0498-331 |
0.305 |
|
| Show low-probability matches. |